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Body dysmorphic disorder: a treatment synthesis and 
consensus on behalf of the International College of 
Obsessive-Compulsive Spectrum Disorders and the 
Obsessive Compulsive and Related Disorders Network of the 
European College of Neuropsychopharmacology
David Castlea, Francesca Beilharzb, Katharine A. Phillipsc,  
Vlasios Brakouliasd, Lynne M. Drummonde, Eric Hollanderf,  
Konstantinos Ioannidisg, Stefano Pallantif,h,  
Samuel R. Chamberlaini,j,k,l, Susan L. Rossellm, David Vealen,  
Sabine Wilhelmo, Michael Van Ameringenp, Bernardo Dell’Ossoq,  
Jose M. Menchonr and Naomi A. Finebergs                  
Body dysmorphic disorder (BDD) is characterized by 
a preoccupation with a perceived appearance flaw 
or flaws that are not observable to others. BDD is 
associated with distress and impairment of functioning. 
Psychiatric comorbidities, including depression, social 
anxiety, and obsessive-compulsive disorder are common 
and impact treatment. Treatment should encompass 
psychoeducation, particularly addressing the dangers 
associated with cosmetic procedures, and may require 
high doses of selective serotonin reuptake inhibitors* 
(SSRI*) and protracted periods to establish full benefit. 
If there is an inadequate response to SSRIs, various 
adjunctive medications can be employed including atypical 
antipsychotics*, anxiolytics*, and the anticonvulsant 
levetiracetam*. However, large-scale randomized controlled 
trials are lacking and BDD is not an approved indication for 
these medications. Oxytocin* may have a potential role in 
treating BDD, but this requires further exploration. Cognitive-
behavioural therapy has good evidence for efficacy for 
BDD, and on-line and telephone-assisted forms of therapy 
are showing promise. CBT for BDD should be customized 
to address such issues as mirror use, perturbations of 
gaze, and misinterpretation of others’ emotions, as well as 
overvalued ideas about how others view the individual. Int 
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Introduction
Body dysmorphic disorder (BDD) is a recognized psy-
chiatric disorder characterized by a preoccupation that 
some aspect of the sufferer’s physical appearance is 
ugly or perception of disfigurement, to the extent that 
they experience significant distress, disability or both. 
Frequently, there is no obvious abnormality in the indi-
vidual’s appearance, but sometimes there is a minor flaw 
which is not immediately obvious to others and, in both 
cases, the individual’s response is excessive (Phillips et al., 
1993; Castle et al., 2006; American Psychiatric Association, 
2013). The Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition (DSM-5) has included BDD 
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in the chapter on Obsessive-Compulsive and Related 
Disorders (OCRDs; American Psychiatric Association, 
2013). The upcoming 11th edition of the International 
Classification of Diseases (ICD-11) takes a rather broader 
and more culturally informed approach to BDD but also 
plans to include it within the OCRDs grouping (https://
icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.
int%2ficd%2fentity%2f731724655; Veale and Matsunaga, 
2014).
The community point prevalence of BDD in nationwide 
studies has been estimated at around 1.7–2.9% (Rief et 
al., 2006; Koran et al., 2008; Schieber et al., 2015; Veale et 
al., 2016). Many people with the disorder never come to 
the attention of health professionals, in part because of 
the shame they often feel about their problem. Indeed, 
when many people with BDD look for help, owing to 
limited insight into their problems, they access clinicians 
other than psychiatrists such as dermatologists, cosmetic 
surgeons, etc (see below). BDD tends to have a chronic 
persistent course unless adequately treated (Veale et al., 
1996; Phillips et al., 2013) and can be extremely debilitat-
ing. Suicidal ideation is common (Phillips and Menard, 
2006) and suicide rates are among the highest of any psy-
chiatric disorder. Indeed, a meta-analysis of 17 studies 
reported an odds ratio for suicidality in BDD (relative 
to the general population) of 3.63 (95% CI, 2.62–4.63), 
BDD being associated with significantly higher levels of 
suicidality than other psychiatric disorders characterized 
by high risk for suicidal thoughts and acts (Angelakis et 
al., 2016). People with BDD often have associated with 
social anxiety disorder and depression (Phillips, 2005b). 
There is also substantial overlap in symptoms with obses-
sive-compulsive disorder (OCD). Nevertheless, there are 
some important differences between BDD and OCD in 
terms of symptoms, neurobiology, treatment response, 
and other characteristics (Simberlund and Hollander, 
2017; Malcolm et al., 2018).
This article provides a summary of treatment strate-
gies for BDD, including emerging novel approaches. 
Similarities and differences with OCD are emphasized. 
In spite of its substantial prevalence and morbidity, there 
is no drug officially approved for the treatment of BDD 
and the response to the different treatment strategies 
that have been tested is limited. While different evi-
dence-based clinical guidelines for managing OCD have 
been published (reviewed in Fineberg et al., 2020), there 
is limited available guidance for the treatment of BDD.
The International College of Obsessive-Compulsive 
Spectrum Disorders (www.ICOCS.org) is a global net-
work of expert clinicians, researchers, and ‘experts by 
experience of OCD’, whose principal objective is to 
support and stimulate the study and treatment of obses-
sive-compulsive spectrum disorders. The Obsessive-
Compulsive and Related Disorders Network (OCRN) 
of the ECNP Networks brings together researchers with 
different expertise to foster successful collaboration 
and sharing of ideas, discoveries, and practices in trans-
lational neuroscience. In recognition of the need for 
updated clinical guidance on the treatment of BDD, both 
organizations, the ICOCS and OCRN, have developed 
this treatment synthesis, based on expert consensus. 
Agreement was reached on the key issues to be covered 
and the authors of each section were chosen based on 
their expertise in that area. Briefly, the recent advances 
in the field have been selected by a range of experts who 
have considered those of most relevance to the manage-
ment of BDD. An initial draft was prepared, based on a 
literature review and circulated first among the authors 
and iterative edits were incorporated. Drug treatments 
mentioned along the text have been selected according 
to the evidence from clinical and translational neurosci-
ence, but they have been marked with an asterisk (*) to 
underline that no drug is labeled for BDD.
Initial treatment considerations
A number of important initial considerations should be 
noted when treating patients with BDD. First, unlike 
in OCD, where ‘insight’ is usually retained, people with 
BDD have a high likelihood of holding their beliefs 
about their appearance with delusional conviction (Toh 
et al., 2017b). BDDs delusional variant used to be con-
sidered a form of BDD which required additional DSM 
coding with delusional disorder; this has been aban-
doned in DSM-5, and an ‘insight specifier’ has been 
adopted (American Psychiatric Association, 2013), such 
that BDD may be coded as being characterized by good 
or fair insight, poor insight, or absent insight (delusional 
beliefs). ICD-11 does not propose any additional cod-
ing for BDD patients whose appearance beliefs are held 
with delusional conviction but condensed to two distinct 
levels of insight with fair to good insight and with poor 
to absent insight, for all OCRDs (Veale and Matsunaga, 
2014). Many in the field pragmatically consider ‘delu-
sional’ BDD simply to reflect the severe end of the BDD 
spectrum (Labuschagne et al., 2010; Rossell et al., 2020); 
importantly, it is recognized that antipsychotic agents do 
not appear to be effective as monotherapy even if BDD 
is ‘delusional’ (Mancuso et al., 2010).
Because insight in people with BDD is usually absent or 
poor (i.e. they are usually mostly or completely convinced 
that they look abnormal, ugly, or deformed), they may be 
reluctant to participate in mental health treatment; many 
prefer to receive cosmetic treatment, which is not recom-
mended (see below). Thus, motivational strategies and 
more extensive psychoeducation may be required than 
for many other psychiatric disorders in order to engage 
and retain these patients in treatment (Veale et al., 2017).
Second, it is common for people with BDD to have a 
number of psychiatric comorbidities (although this is also 
the norm for most other psychiatric disorders if patients 
are systematically assessed for comorbidity). For exam-
ple, in the study of Phillips et al. (1994), lifetime rates of 
psychiatric comorbidity among 100 BDD patients were 
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80% for major depressive disorder, 37% for social pho-
bia, and 34% for OCD. A more recent study of 293 BDD 
patients confirms these associations and also emphasizes 
the extent of triple or even quadruple comorbidities: for 
example, only 2% had social anxiety disorder alone, while 
32% had social anxiety disorder plus depression and 14% 
had these two comorbidities plus OCD (Gunstad and 
Phillips, 2003). It is important to note that the studies of 
Phillips et al. (1994) and of Gunstad and Phillips (2003) 
consisted of samples who were seeking or receiving treat-
ment, and the rates of comorbidities would be expected 
to be lower in community samples (Toh et al., 2017c) or 
nonspecialist settings. In any event, the presence of such 
comorbidities requires therapeutic interventions to be 
sufficiently nuanced to adjust the treatment accordingly. 
For cognitive-behavioural therapy (CBT), usually, a hier-
archical approach is appropriate, with the most severe 
and disabling condition being prioritized (i.e. treated 
first) or explicitly worked into the treatment framework 
(Wilhelm et al., 2013).
In some instances, the treatments for BDD are also use-
ful for comorbid conditions. For instance, serotonergic 
antidepressants can be effective for the core symptoms 
of BDD but can also help address multiple other comor-
bidities, such as depressive and social anxiety comorbid-
ity as well as comorbid OCD symptoms. Similarly, CBT 
for BDD is also associated with improvement in certain 
associated symptoms such as depression (Veale et al., 
2014; Wilhelm et al., 2014; 2016). Other comorbidities 
are more difficult, notably bipolar disorder, where high 
doses of serotonin reuptake inhibitors (SRIs; the first-line 
pharmacotherapy for BDD) can destabilize mood; how-
ever, patients who are first adequately treated with one or 
more mood stabilizers can be treated with SRIs with less 
difficulty. Comorbid anorexia nervosa is particularly chal-
lenging in patients with BDD (Phillipou et al., 2019), with 
the emphasis usually being initially on the disordered 
eating and ensuring medical stability. Suicidal ideation 
and acts are common in people with BDD, and careful 
attention needs to be given to assessment and appropri-
ate interventions. Substance use disorders are also com-
mon in people with BDD, which are often an attempt to 
cope with BDD-related distress. Both the substance use 
disorder and BDD need to be a focus of treatment.
Skin picking and hair pulling require a particular 
approach, in that people with BDD often engage in these 
activities to try to fix their perceived skin or hair ‘defects’ 
by removing skin irregularities, blemishes, or disliked 
hairs. This differs from the more impulsive picking/pull-
ing seen in excoriation (skin-picking) disorder or tricho-
tillomania, which are not triggered by thoughts that the 
skin or hair look abnormal or ugly (Veale and Matsunaga, 
2014). Thus, the therapeutic strategies for skin picking or 
hair pulling in people with BDD include interventions 
for excoriation (skin-picking) disorder and trichotilloma-
nia, such as habit reversal, plus additional BDD-specific 
strategies.
A third issue is that BDD has a particular variant, where 
the focus of concern is body habitus, the individual ‘seeing’ 
their body composition as puny or slight, when it is actu-
ally normal or even very muscular, and seeking to achieve 
a muscular ideal (American Psychiatric Association, 2013). 
This form of BDD (muscle dysmorphia) largely occurs 
in males and encompasses a number of behaviours not 
usually evident in people with BDD, notably excessive 
muscle-enhancing exercises; specific low-fat, high protein 
diets; and the use of supplements and potentially danger-
ous anabolic steroids, testosterone, and medications such as 
thyroid hormone, insulin, and estrogen modulators (which 
may be illicitly obtained) (Tod et al., 2016; Blomeley et al., 
2018). These issues add a further layer of complexity to 
BDD management and require attention to the habitual 
exercise and dietary regimens as well as advice about and 
treatment for abuse of muscle-enhancing agents and other 
substances if abused. It should be noted that unlike the 
DSM 5 working group, the ICD-11 working group did not 
consider muscle dysmorphia to be ‘sufficiently different’ 
from other manifestations of BDD to warrant an additional 
specifier (Veale and Matsunaga, 2014).
There appear to be some differences in the presenta-
tion of BDD and the body parts which are focused on 
in men and women, although BDD in men and women 
has many more similarities than differences. In women, 
BDD is more likely to be comorbid with an eating disor-
der, whereas in men BDD is more likely to be comorbid 
with a substance use disorder, which has implications for 
treatment (Grant and Phillips, 2004; Tyagi et al., 2012; 
Gazzarrini and Perugi, 2017).
A final consideration pertains to how we define response 
and remission in treatment trials of BDD. Most clini-
cal trials use the well-validated Yale-Brown Obsessive 
Compulsive Scale modified for BDD (BDD-YBOCS) 
(Phillips et al., 1997). Recently, Fernandez de la Cruz et al. 
(2019) pooled data from three CBT trials for BDD con-
ducted across three countries (combined n = 153), to eval-
uate the way in which BDD-YBOCS performed in terms 
of predicting either response or remission. A reduction in 
scores of ≥30% on the BDD-YBOCS predicted response 
against the Clinical Global Impression Scale with a sen-
sitivity of 0.89 and specificity of 0.91, while partial or full 
remission was best predicted by a BDD-YBOCS score 
of ≤16 (sensitivity 0.85 and specificity 0.99). These cut-
offs should thus be seen as the benchmarks for future 
research, but some published studies used different cut-
offs and need to be interpreted in this light.
General treatment issues
One of the key issues in treating people with BDD is 
to ensure that it is recognized. As people with BDD 
often seek redress through cosmetic means (see below), 
screening for BDD within such settings seems appropri-
ate. It has also been shown that most physicians have a 
low level of recognition of BDD, and even in psychiatric 
settings, it is often missed. Sensitive questioning and the 
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use of validated screening tools can enhance recognition 
and thus engagement in treatment. Such tools include:
(1) The Dysmorphic Concern Questionnaire (Oosthuizen 
et al., 1998): This is a seven-item scale with each item 
scored from 0 (‘not at all’) to 3 (‘much more than most 
people’): the minimum score is 0 and the maximum is 
21; a cutoff for BDD is 9 (Mancuso et al., 2010).
(2) The Body Dysmorphic Disorder Questionnaire 
(BDD-Q) (Phillips, 1996a; 2005a): This simple, brief 
self-report questionnaire screens for the presence 
of BDD. The BDDQ has excellent sensitivity and 
specificity for DSM-IV BDD in mental health and 
cosmetic treatment settings. It is also suitable for 
screening for DSM-5-defined BDD.
(3) Body Dysmorphic Disorder Questionnaire-
Dermatology Version (BDDQ – Dermatology Version) 
(Dufresne et al., 2001): this simple, brief self-report 
questionnaire screens for the presence of BDD. It is 
very similar to the BDDQ (described above); some 
of the BDDQs dichotomized yes/no questions are 
instead scored on five-point Likert scales. This ver-
sion of the BDD-Q also has strong psychometric 
properties.
(4) The Cosmetic Procedure Screening Questionnaire for 
BDD (Veale et al., 2012): Nine items cover essential 
features of BDD, each rated from 0 (‘least impaired’) 
to 8 (‘most impaired’). It was developed to screen for 
BDD in people seeking cosmetic procedures, with 
a score of 40 or over being and an indicator that the 
individual requires a full assessment for BDD.
As with all psychiatric disorders, effective and thor-
ough psychoeducation is an important core feature of a 
therapeutic framework for BDD. There is a number of 
useful self-help books, including ‘The Broken Mirror: 
Understanding and Treating Body Dysmorphic Disorder’ 
(Phillips, 1996a; 2005a); ‘Feeling Good About the Way 
You Look: A program for overcoming body image prob-
lems’ (Wilhelm, 2006); and ‘Overcoming Body Image 
Problems (including Body Dysmorphic Disorder)’ (Veale 
et al., 2009). Online interventions are also being devel-
oped and evaluated, as discussed below.
A very important consideration in BDD is that most 
affected people see their problem as physical rather 
than psychological or psychiatric, and thus seek cos-
metic redress. The prevalence of BDD among people 
attending cosmetic specialists is high: rates of 12.3% 
have been reported in general cosmetic surgery settings, 
20.1% in rhinoplasty patients, 5.2% in orthodontics/
cosmetic dentistry, and 9.2% in cosmetic dermatology 
(Veale et al., 2016). The majority of BDD patients have 
sought or received cosmetic treatment for BDD appear-
ance concerns. A broad array of clinicians may be seen, 
such as dermatologists, plastic surgeons, maxillo-facial 
surgeons, and trichologists. In the largest study of this 
topic (n = 250 adults with BDD), 76% of patients had 
sought cosmetic treatment (surgical, dermatologic, and 
other types of cosmetic interventions) in an attempt to 
fix their perceived appearance concerns, and 66% had 
actually received aesthetic treatments, with 72% having 
sought and 60% having received treatment from either a 
dermatologist or a cosmetic surgeon (Phillips et al., 2001). 
Findings were nearly identical in a different and more 
broadly ascertained sample of 200 individuals with BDD 
(Crerand et al., 2005). There are also reports of BDD 
patients performing “DIY (do it yourself) surgery” when 
they cannot persuade cosmetic specialists to undertake 
their desired procedure (Phillips, 1996a; Veale, 2000).
It is important for mental health clinicians dealing with 
people with BDD to have a clear and candid discussion 
about these matters and provide warnings about the 
very low likelihood of cosmetic interventions helping 
the BDD symptoms in the longer term: some people 
with BDD experience some brief ‘relief’ after a cos-
metic procedure but often become dissatisfied with the 
outcome and/or seek further procedures for the same or 
another physical ‘defect’ (Phillips et al., 2001; Crerand 
et al., 2005). There may be some exceptions to this rule. 
For example, Veale et al. (2014) found that labiaplasty 
may carry a good psychosocial outcome even in patients 
with BDD; the same might occur for breast augmen-
tation. However, the American College of Obstetrics 
and Gynaecology has stipulated caution needs to be 
exercised in any such procedures being undertaken in 
people with BDD (American College of Obstetricians 
and Gynecologists, 2017; 2020). More positive views 
of surgical outcomes with BDD are controversial, and 
BDD is widely considered a contraindication for cos-
metic surgery. Facial procedures such as rhinoplasty are 
much more likely to have complex psychological out-
comes, even in people without BDD (Honigman et al., 
2004).
The study of Tignol et al. (2007) is particularly instructive. 
These authors performed a 5-year follow-up of 24 of 30 
individuals with ‘minimal defect in appearance’ request-
ing cosmetic surgery (12 were diagnosed with BDD at 
baseline, of whom 10 were followed up). Fifteen individ-
uals underwent cosmetic procedures. Self-reported satis-
faction with the cosmetic outcome was in general high. 
However, at follow-up, six of the seven BDD patients 
who underwent cosmetic surgery still met the criteria 
for BDD and carried higher levels of disability and psy-
chiatric comorbidity than those without a baseline BDD 
diagnosis. Also, three non-BDD individuals ‘developed’ 
BDD over the follow-up period, reflecting the fact that 
the focus of concern may switch to a different body part 
following cosmetic surgery.
Thus, it is recommended to try to reach an agreement 
with the patient not to pursue such procedures. At the 
very least, they should be delayed until psychological 
and pharmacological approaches can be given an oppor-
tunity to show efficacy (6–12 months). Where appropri-
ate, liaison with the cosmetic specialist can be fruitful, 
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in discussing all potential risks and ensuring psychiatric 
assessment and treatment are affected.
Pharmacotherapy
Like OCD, the mainstay pharmacological therapies 
for BDD are SRIs, that is, selective serotonin reuptake 
inhibitors* (SSRIs) and clomipramine*. Predominantly 
noradrenergic antidepressants* have not proven effective 
for BDD. For example, Hollander et al. (1999) performed 
a randomized controlled cross-over study of 29 adult 
patients with BDD comparing clomipramine (predomi-
nantly SRI) with desipramine [predominantly noradren-
aline reuptake inhibition (NRI)] and showed superiority 
for the former agent in ameliorating BDD symptoms 
[65% response (defined as ≥25% reduction in BDD-
YBOCS) with clomipramine vs. 35% with desipramine]. 
Importantly, the effects were independent of mood, 
underlining the primacy of serotonergic perturbations in 
BDD. This selective efficacy of SRIs vs. NRIs in BDD is 
similar to that found in OCD (Goodman et al., 1990), and 
is one criterion that is supportive of the inclusion of BDD 
as an OCRD in classification manuals.
Randomized placebo-controlled controlled trials in BDD 
have been reviewed by Phillipou et al. (2016a). Three tri-
als met the inclusion criteria of being empirical research 
specifically of BDD patients, published in peer-reviewed 
journals in English, employing a controlled randomized 
design and reporting BDD symptoms pre- and post inter-
vention. One of these studies is the aforementioned cross-
over trial of Hollander et al. (1999). The other two were 
both from the same laboratory and had some overlap in 
terms of participants. The earlier of these two studies 
(Phillips et al., 2002) randomized 67 BDD adult patients 
to an initial dose of 20 mg fluoxetine* daily, or placebo. 
Fluoxetine dose could be increased every 10 days, up to 
a maximum of 80 mg daily. Three patients in the fluox-
etine arm and five in the placebo arm withdrew prior to 
study completion. Using a BDD-YBOCS reduction of 
≥30% to define response, 53% of the fluoxetine group 
met response criteria, compared with 18% on placebo, 
a statistically significant difference. Response of BDD 
was independent of response of major depressive disor-
der, OCD, or a personality disorder. Importantly, fluoxe-
tine had a protective effect against suicidality worsening 
(Phillips and Kelly, 2009). Phillips (2005b) also utilized a 
placebo-controlled randomized design to study augmen-
tation with a typical neuroleptic* in BDD. The authors 
included 19 participants from the earlier study, as well as 
a further nine additional patients (i.e. total n = 28), all of 
whom had received fluoxetine for at least 12 weeks, at a 
dose of 80 mg per day, if tolerated: none had adequately 
responded to fluoxetine. Eleven of these patients were 
randomized to pimozide* (initially 1 mg daily, increasing 
step-wise to a maximum of 8 mg daily) and 17 to placebo, 
over 8 weeks, while remaining on a fixed fluoxetine dose 
schedule. There was a substantial drop-out, with only 6 
pimozide patients and 11 placebo patients completing 
the study. There was no advantage seen for pimozide 
over placebo for BDD symptom reduction; although the 
sample size was small the effect size was also small [after 
this study was completed, the combination of pimozide 
and SRIs became contraindicated in the USA due to con-
cerns about the potential for corrected QT interval (QTc) 
prolongation].
Since the publication of the review by Phillipou et al. 
(2016b), an additional study compared the efficacy of 
continuation pharmacotherapy in people with BDD who 
initially responded to medication. Phillips et al. (2016) 
treated 100 BDD adult patients with open-label escitalo-
pram* [mean dose at the end of 14 weeks was 26.2 mg/
day (SD 7.2)], whereafter responders (n = 58) were rand-
omized to continuation pharmacotherapy or placebo, and 
followed for a further 6 months. The continuation phase 
showed that relapse was significantly reduced in the 
active treatment group (18 vs. 40% for placebo); and time 
to relapse was significantly delayed [hazard ratio 2.72 
(95% CI, 1.01–8.57)]. Importantly, additional improve-
ment in BDD symptoms was noted in over a third of 
participants in the escitalopram continuation phase, sup-
porting clinical observations that benefits from SRIs can 
continue to accrue over extended time periods.
Despite the limited randomized controlled trials (RCTs) 
of SRIs in BDD, with the use of fluoxetine*, clomi-
pramine*, or escitalopram*, it can reasonably be assumed 
that other SRIs* are also effective for BDD, as is the case 
for other psychiatric disorders. In clinical practice, they 
are often used largely interchangeably, depending upon 
efficacy, tolerability, and treatment history. Furthermore, 
in a chart-review study of 90 patients who had received 
an SRI in clinical practice, response rates were similar for 
each type of SRI (Phillips et al., 2001).
A number of these agents has been investigated in open 
trials or reported as case series. Phillips and Najjar (2003) 
found that citalopram* (mean dose 51.3 ± 16.9 mg/day) 
improved BDD symptoms in over 80% of a group of 
15 patients, as well as the quality of life, over 12 weeks. 
Escitalopram* (mean dose 28 ± 6.5 mg/day) showed 
similar favourable outcomes on BDD symptoms (73% 
response rate) in an open trial of 15 patients over 12 weeks 
(Phillips, 2006), as did fluvoxamine* (mean dose 238 mg/
day ± 85 mg per day) in 30 patients treated for a mean 
of 6.1 (±3.7) weeks (Phillips et al., 1998). In all of the 
above studies, participants with the delusional variant 
of BDD (under DSM-IV nosology: see above; American 
Psychiatric Association, 1980) showed similar response 
rates to those whose beliefs were not delusional; most 
studies also found that insight significantly improved 
with treatment.
Like OCD, doses of SRIs employed in BDD are often 
higher than those usually used for depression. Doses of 
300 mg or 400 mg a day of sertraline* equivalent may 
be required for efficacy. Maximum doses for the various 
SSRIs are: sertraline 400 mg/day, fluoxetine* 120 mg/
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day, citalopram* 40 mg/day; escitalopram* 60 mg/day 
(with an ECG recommended at doses exceeding 20 mg/
day), fluvoxamine* 450 mg/day; and paroxetine* 100 mg/
day. These doses are above the maximum dosages rec-
ommended by most countries’ regulatory agencies, and 
patients need to be made aware of this. However, they 
are identical to maximum doses for OCD in the American 
Psychiatric Association’s (2007) Practice Guideline for 
OCD (with the exception of citalopram, as the maximum 
dose has since been lowered). In addition, the SSRIs 
have a high therapeutic index, and the higher doses are 
usually well tolerated.
There is a very low risk of serotonin syndrome and some 
concerns regarding prolongation of the QTc interval, 
albeit initial warnings about citalopram in this regard 
have not been supported by subsequent scrutiny of the 
relevant data (Hutton et al., 2017). Having said this, it 
would be sensible to obtain an ECG when there is any 
history of cardiac conduction problems and when using 
escitalopram* at doses exceeding 20 mg/day and citalo-
pram*, which has a black box warning regarding QTc 
prolongation at daily doses above 40 mg. Some experts 
would check an ECG for any SSRI when the dose being 
used is above the maximum recommended by regula-
tory agencies. However, clinical practices in this regard 
vary somewhat among pharmacotherapy experts. For 
example, a participant of the present consensus (K.A.P.) 
does not obtain ECGs solely when using doses above the 
regulatory maximum (except for escitalopram at 40 mg/
day or higher) and does not use citalopram for BDD 
because the US regulatory maximum dose of 40 mg/day 
is firmer than for the other SSRIs and is often too low 
to treat BDD effectively. Also, as in OCD, the effects of 
medication might take some weeks to accrue, hence a 
step-wise dosing schedule is suggested, with 2–3 weekly 
increases dependent upon efficacy and tolerability. A 
slower schedule with a lower total dose is recommended 
in youth, those with sensitivity to medication side effects, 
the elderly, and people with physical comorbidities, such 
as hepatic dysfunction and cardiac conduction problems.
Whether clomipramine* has any added benefit for BDD 
over the SSRIs remains unstudied, but some patients do 
respond well to it: the side effects, notably histaminer-
gic and muscarinic anticholinergic effects such as weight 
gain, sedation, dry mouth, and orthostatic hypotension 
can limit dose. Daily doses of up to 250 mg have been 
used, albeit some patients respond to lower doses or 
cannot tolerate the higher doses. Monitoring of ECGs 
and blood levels is recommended, with dosing guided 
by blood levels. A dose of 250 mg/day should not be 
exceeded due to this medication’s low therapeutic index. 
We know of only a single published study of intravenous 
clomipramine in BDD. In that study (Pallanti and Koran, 
1996), two patients meeting DSM-IV criteria for BDD 
(delusional variant) were administered pulse-loaded 
intravenous clomipramine (150 mg on day 1, 200 mg on 
day 2). Both patients showed around a 30% reduction 
in BBD-YBOCS scores 4.5 days after intravenous dos-
ing, and improved further over the ensuing two months 
on oral medication, with marked improvement in social 
functioning. These authors suggest that pulse-loaded, 
intravenous clomipramine may have benefits for rapid 
symptom reduction in some people with BDD.
There are earlier case reports of patients with BDD 
responding to other tricyclic antidepressants*, including 
doxepin* (200 mg daily) (Brotman and Jenike, 1984) as 
well as the monoamine oxidase inhibitor (MAOI) tranyl-
cypromine* (30 mg daily) (Jenike, 1984). However, avail-
able data (case series) indicate that these medications are 
unlikely to be efficacious for BDD (Phillips et al., 1993; 
1994) and thus their use is not routinely recommended. 
However, MAOIs* have been found to be useful for peo-
ple with a severe social anxiety disorder (Menkes et al., 
2016), raising the question of whether they might be use-
ful in BDD patients with pervasive and severe social anx-
iety, but this question remains to be empirically tested, 
and these medications are complicated to prescribe and 
can be difficult to tolerate.
In BDD treatment, a 12–14 week trial of an SRI* is 
recommended, with at least 3–4 of these weeks at the 
maximum dose recommended by regulatory agencies, 
in order to determine whether the medication is helpful 
enough to continue it. A longer trial is needed if slower 
titration is used. Duration of therapy is usually guided by 
clinical response and any side effects experienced. With 
SSRIs, sexual side effects may occur and can lead to dis-
continuation (Read and Williams, 2018); however, sexual 
functioning is often impaired due to BDD or comorbid 
depression and may therefore improve with SRI treat-
ment. In addition, sexual side effects may resolve with 
time (up to 6 months or so), and, if not, treatment for 
more problematic or persistent sexual dysfunction may 
be effective.
In the only published long-term double-blind rand-
omized discontinuation study in the field (detailed 
above), Phillips et al. (2016) found benefits with con-
tinued escitalopram* over a 6-month period beyond 
the acute treatment phase of 14 weeks. Studies over a 
longer time period are required, but clinical experience 
suggests continuing with the dose which was initially 
effective for at least several years and then, if indicated, 
trying a gradual staged reduction with careful monitoring 
for recurrence of symptoms. However, BDD is a chronic 
condition, and patients often remain on their medication 
indefinitely, similarly to OCD patients. For those with 
multiple hospitalizations and/or suicide attempts, indefi-
nite treatment with medication is usually recommended.
Adjunctive pharmacologic agents
As with OCD, many people with BDD do not experience 
full resolution of symptoms with SSRIs*. In this scenario, 
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the usual clinical practice would be to increase the dose 
of the SSRI above regulatory maximum doses (except 
for clomipramine* and citalopram*), to the doses, noted 
previously, which not uncommonly improves symptoms. 
Alternatively, the clinician can try a different SSRI or clo-
mipramine. If such measures fail, a number of adjunctive 
medications can justifiably be used. Of course, due atten-
tion needs to be paid to drug–drug interactions and the 
potential for cumulative side effects.
Antipsychotics
Perhaps informed by evidence for the efficacy of antip-
sychotics* as adjuncts to SRIs in OCD (Kim et al., 2018; 
Brakoulias and Stockings, 2019), practitioners have pre-
scribed these agents for BDD. The assumption that effi-
cacy in OCD necessarily translates to efficacy in BDD is 
not necessarily valid, as the underlying neurobiology of 
the conditions differs from each other in certain respects 
(Rossell et al., 2015; Grace et al., 2017; Malcolm et al., 2018). 
In part, the use of antipsychotics in BDD is also driven by 
an implicit assumption that, because BDD patients are 
sometimes ‘psychotic’ in the sense that they hold their 
beliefs with delusional conviction, they require an antip-
sychotic. Nevertheless, such an assumption is again not 
supported by clinical studies, which show that even ‘psy-
chotic’ BDD can respond to SRIs* alone (Phillips, 2017). 
Also, BDD may be comorbid with bipolar disorder in 
clinical practice, in which case mood-stabilizing antipsy-
chotics are often required as a first step in the treatment 
hierarchy prior to using SSRIs to treat the BDD.
Very few studies have formally evaluated the use of 
antipsychotics* as augmenting agents for BDD, and most 
have actually been negative. The only published RCT 
is the small add-on study using pimozide*, discussed 
above (Phillips, 2005b). Phillips (2005b) also reported 
an open-label study (n = 6) with olanzapine* [mean dose 
mean dose 4.6 mg/day (SD 3.3)] as an adjunct to fluoxe-
tine* (mean dose 70 mg), which did not show any bene-
fits in terms of BDD symptoms for four participants and 
minimal benefit in a further two. Despite these negative 
findings, the use of antipsychotics in BDD patients, who 
have failed to respond to SRIs, is common in specialist 
practice (Rashid et al., 2014). Case reports have described 
potential benefits from the addition of olanzapine* 
(Grant, 2001; Nakaaki et al., 2008), quetiapine* (Mancuso 
et al., 2010), and risperidone* (Goulia et al., 2011) to an 
SRI, in some BDD patients. Case reports, of course, suf-
fer from reporting and publication bias, and there is little 
clarity about which BDD patients are particularly likely 
to respond to which of these agents. As always, potential 
side effects need to be weighed against potential benefits.
The dopamine D2 partial agonist aripiprazole* has been 
used in clinical practice as an SRI* augmenting agent in 
BDD. Again, no open-label or RCTs have been conducted, 
but the use in BDD mirrors the use of aripiprazole in 
OCD as well as in depression (Veale et al., 2014). Beneficial 
effects can be seen for both BDD and mood. Doses usually 
range from 2 to 10 mg per day. In the only published report 
of which we are aware, that specifically used aripiprazole 
in BDD, Uzun and Ozdemir (2010) successfully treated a 
43-year-old woman with BDD with the addition of 10 mg 
aripiprazole to 400 mg fluvoxamine. In the experience of 
some of this article’s authors, this medication may be quite 
effective as an SRI augmentation agent. We are aware of 
no published studies of the newer dopamine D2 partial 
agonists (brexpiprazole* and cariprazine*) in BDD. It is 
important to keep in mind that antipsychotics are a large 
class of medications, with varying efficacy for different 
symptoms (Huhn et al., 2019). In the authors’ experience 
and opinion, second-generation antipsychotics are more 
likely than the first-generation antipsychotics to be effica-
cious for BDD and accompanying depression. Research on 
this important issue is greatly needed.
Other pharmacologic agents
Many other augmenting strategies have been employed 
in specialist practice to try to help people with BDD, 
but none have been subject to robust research evalua-
tion. The field is again guided to a large extent by the 
experience of augmenting agents in OCD. We would 
advocate for an approach to augmentation that responds 
to the particular profile of the individual and which tar-
gets specific symptom sets. For example, patients with 
features of generalized anxiety might benefit from 
buspirone*, clonazepam*, or pregabalin*. All of these 
agents are off-label for BDD and clonazepam has the 
potential for habituation and addiction. Phillips (1996b) 
showed in a small open trial that buspirone (mean dose 
48.3 mg/day) was beneficial as an add-on to fluoxetine* 
or clomipramine* in 46% of 13 BDD patients, but we are 
aware of no specific published trials using clonazepam or 
pregabalin in BDD. There is some evidence that the sup-
plement N-acetylcysteine* may be efficacious for OCD, 
and clinical experience suggests that it can be helpful as 
an SRI adjunct in BDD. Also, intranasal esketamine* has 
been used in clinical practice with some benefit for BDD 
comorbid with resistant depression (unpublished data).
A small open-label trial (n = 17) showed significant 
improvement with the anticonvulsant levetiracetam* 
(500–2000 mg per day) in patients with BDD (Phillips and 
Kelly, 2009). It can be used either as an adjunct to an SSRI 
or as monotherapy. Another small open-label trial (n = 17) 
with the serotonin–norepinephrine reuptake inhibitor 
venlafaxine* similarly led to significant improvement in 
BDD symptoms (Allen et al., 2008). However, due to the 
lack of RCTs and small sample sizes, these medications 
should be used only when optimized SRI trials have not 
been effective.
Medications under investigation for BDD have been 
recently reviewed by Dong et al. (2019). These agents 
include silymarin* (an extract of milk thistle) and 
memantine*, based on their efficacy for some patients 
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with OCD. Results of these studies have not yet been 
reported but will clearly be of interest in terms of new 
therapeutic modalities for BDD and can also inform 
understandings of underlying neurobiology.
Psychological approaches:
An early review and meta-analysis (Williams et al., 2006) 
of treatments for BDD included case series as well as 
RCTs. There were nine studies that employed psycho-
logical therapies, but there was substantial heterogene-
ity. The results suggested similar efficacy for exposure/
response prevention (ERP) and CBT in BDD, with effect 
sizes of 1.43 and 1.78, respectively. The more recent sys-
tematic review of Phillipou et al. (2016a) found six RCTs 
of psychological interventions in BDD, with a total of 165 
participants (range 10–53) reaching the predefined study 
end-point (ranging from 8 to 24 weeks): drop-out rates 
ranged from 0 to 33.3%. All studies were arguably under-
powered and many did not define a specific response cri-
terion. Most had waitlist control conditions (Rosen et al., 
1995; Veale et al., 1996; Rabiei et al., 2012; Wilhelm et al., 
2014), while in the study of McKay et al. (1997), there was 
no treatment offered to controls. Lack of active controls 
does not allow determination of the effect of study par-
ticipation parameters, such as clinician contact time and 
attention. A notable exception is one of the studies by 
Veale et al. (2014), which employed an anxiety manage-
ment comparator.
The content of the therapy across these studies was fairly 
heterogeneous. Most used some variant of CBT but the 
additional content (e.g. the study of Wilhelm et al. (2014) 
included advanced cognitive restructuring and additional 
optional modules (for patients who had relevant symp-
toms) addressing skin picking, muscularity concerns 
(muscle dysmorphia), cosmetic treatment, and mood 
management, and format, duration and time between 
sessions were variable. Rabiei et al. (2012) employed a 
metacognitive approach, while McKay et al. (1997) essen-
tially used ERP strategies. Furthermore, not all samples 
were representative of BDD patients in the community: 
for example, Rosen et al. (1995) included only females, 
most of whom had predominantly weight and shape 
concerns.
Given the heterogeneity and major methodological 
differences across studies, Phillipou et al. (2016a) did 
not believe the data met the criteria for meta-analysis. 
Subsequently, Harrison et al. (2016) performed a system-
atic review and meta-analysis of randomized controlled 
studies of CBT in BDD. They included seven studies 
(total n = 299) and reported CBT to be superior to wait-
list or psychological placebo in reducing BDD symp-
toms (seven studies: delta −1.22; 95% CI −1.66 to −0.79) 
as well as depression (five studies: delta −0.49; 95% CI, 
−0.76 to −0.22). They also found four studies specifically 
addressing BDD-related insight, with an overall benefi-
cial effect of CBT (delta −0.56; 95% CI −0.93 to −0.19). 
‘Delusional’ BDD responded with a similar effect size to 
‘nondelusional’ in most CBT trials.
As pointed out by Menin (2019), many published psy-
chological trials in BDD have substantial methodolog-
ical constraints, including issues with randomization, 
blinding, use of active vs. ‘placebo’ comparators, and 
lack of manualization and specification of the interven-
tion. It is also the case that many of these studies were 
small and thus were statistically underpowered. Many of 
the pharmacological treatment trials in BDD had some 
of the same limitations, as outlined above. On the other 
hand, many of the CBT trials were earlier proof of con-
cept studies, and trials using a wait-list control group are 
generally warranted before embarking on large, expen-
sive, and labour-intensive controlled trials. Some of these 
studies also had particular strengths, such as appropriate 
randomization and use of manualized treatment.
In this context, a recent 24-week RCT (Wilhelm et al., 
2019) comparing supportive psychotherapy (SPT) with 
CBT for BDD (CBT-BDD) addresses many of these 
methodological constraints. The study was adequately 
powered (n = 120); the intervention was manualized 
and specifically developed for BDD; randomization and 
blinding were of high quality; and analyses employed 
intention-to-treat. Overall outcomes were excellent, with 
84% of the CBT-BDD participants meeting response 
criteria; most maintained gains at 6-month follow-up. 
However, the difference in effectiveness between CBT-
BDD and SPT was site-specific: at one site, no significant 
difference was detected, whereas, at the other site, CBT-
BDD led to significantly greater reductions in BDD, 
compared with SPT. One site showed a response rate to 
SPT of 46%, and the other 64%: in fact, analysis of data 
from the second site did not show statistical separation 
from CBT-BDD. The authors of the article suggest the 
high response to SPT at the second site might reflect 
the fact that that site offers predoctoral and postdoc-
toral training in supportive or integrative psychotherapy. 
Thus, SPT at that site is likely superior to that offered in 
other academic medical or community settings, includ-
ing the other site in this study. In addition, because SPT 
primarily emphasizes common factors (rather than spe-
cific skills, as CBT does), therapist factors may have had 
a greater effect on treatment, leading to more variable 
outcomes across the two sites. Of course, this was not just 
‘any’ SPT, as it was being delivered as part of a treatment 
trial, at a site that specializes in both BDD and SPT, and 
with considerable patient contact time. But STP has been 
shown to be effective for depression, albeit with a small 
effect size (Cuijpers et al., 2012). Overall, there is a need 
for appropriately powered controlled trials performed in 
general psychiatric settings to test the efficacy of thera-
pies in a wider context.
One potential method of enhancing CBT is with a phar-
macologic agent such a D-cycloserine* (DCS) that may 
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boost extinction learning that occurs during exposure 
exercises. DCS augmented behaviour therapy has been 
tested with mixed results in disorders similar to BDD. 
Weingarden et al. (2019) conducted a double-blind RCT 
comparing DCS to placebo-augmented CBT for BDD 
(N = 26). Over 10 weeks of treatment, BDD severity as 
well as insight and depression improved significantly 
in both treatment arms, but there were no differences 
between the two conditions.
So-called ‘third wave’ psychological therapies are increas-
ingly popular and are gaining an evidence base across a 
number of psychiatric disorders. There is some emerging 
evidence for efficacy in OCD, notably for Acceptance and 
Commitment Therapy (ACT) (Bluett et al., 2014). For 
BDD, we are aware of no robust clinical trial evidence for 
ACT, but many practitioners incorporate elements of this 
approach in treating such patients, and anecdotally the 
ACT ‘dialogue’ can assist engagement.
Children and adolescents
BDD usually first manifests in childhood or adolescents. 
However, there is often a substantial delay in diagno-
sis and appropriate treatment. In terms of treatments, 
few studies have specifically addressed young people. 
Greenberg et al. (2016) tested CBT outcomes in 13 ado-
lescents with BDD. After 12 sessions, BDD and related 
symptoms (e.g. insight and mood) were significantly 
improved. Seventy-five percent of adolescents who 
started treatment and 100% of completers were treat-
ment responders. Treatment gains were maintained at 
3- and 6-month follow-up.
Mataix-Cols et al. (2015) randomized 30 adolescents with 
BDD and their families, to either 14 sessions of CBT 
delivered over 4 months or a control condition consist-
ing of written psycho-education materials and weekly 
telephone calls. The CBT group showed a significantly 
greater improvement in BDD symptoms (and secondary 
symptoms) than the control group.
SRIs, often at relatively high doses, appear efficacious for 
children and adolescents with BDD. Data are quite lim-
ited in this age group, but clinical experience indicates 
that SRIs are usually efficacious for youth with BDD; in 
addition, in other psychiatric disorders, medications that 
are effective for adults are usually also effective for youth.
In addition to multiple case reports reporting efficacy for 
SRIs in children and adolescents, Phillips et al. (1995) 
described the treatment of four adolescents with severe 
BDD who substantially improved with fluoxetine* or par-
oxetine*. In a subsequent series of 33 children and ado-
lescents with BDD (14.9 ± 2.2 years of age), among those 
treated with an SRI 53% (n = 19) had significant improve-
ment in BDD. In the subset of 13 SRI trials that were 
conducted by the authors, which tended to use higher 
doses than trials not conducted by the authors, 62% led to 
significant improvement in BDD symptoms. In contrast, 
no non-SRI medication was effective in decreasing BDD 
symptoms (Albertini and Phillips, 1999). When treating 
children, it is recommended that SRIs be initiated at 
lower doses than in adults and that doses be limited to 
the regulatory maximum dose.
Online and smartphone-based interventions
Two evidence-based CBT treatment manuals for BDD 
have been published, which enable CBT therapists with-
out expertise in BDD to treat these patients (Veale and 
Neziroglu, 2010; Wilhelm et al., 2013). However, to meet 
the demand for expert psychological care in people with 
BDD, the potential of on-line interventions is exciting. 
Such interventions can also help deliver expert care to 
rural and remote communities, as well as reach people 
who might, due to shame and stigma, not otherwise 
seek appropriate help. Enander et al. (2014) developed 
a 12-week online CBT program for BDD (BDD-NET). 
In an open-label feasibility study of 23 individuals with 
BDD, BDD-NET showed promising outcomes, includ-
ing high acceptability. Significant within-group improve-
ment was found on the BDD-YBOCS [Cohen’s d = 2.01 
(95% CI, 1.05–2.97), representing a large effect size]. 
Fully 82% of participants were classed as responders 
(≥30% reduction in BBD-YBOCS), and gains were main-
tained at 3-month follow-up. Improvements were also 
seen on secondary outcome measures, including global 
functioning, quality of life, and depression.
The same research group (Enander et al., 2016) subse-
quently reported a 12-week single-blind randomized trial 
of BDD-NET (n = 47) vs. SPT delivered via the inter-
net (n = 47). BDD-NET showed superiority to SPT on 
the BDD-YBOCS (group difference −7.1 points; 95% CI, 
−9.8 to −4.4) as well as on ratings of depression, global 
functioning, and quality of life. Among BDD-NET par-
ticipants, 56% were rated as responders vs. 13% of those 
receiving SPT. The number needed to treat was 2.34 
(95% CI, 1.71–4.35) and self-reported satisfaction was 
high. Patients who received SPT were subsequently 
offered BDD-NET and all but four accepted. A 2-year 
follow-up of 88 of the 90 people who had received BDD-
NET (two were lost to follow-up) showed persistence of 
gains for BDD symptoms and global functioning but not 
the quality of life (Enander et al., 2019).
Recently, Gentile et al. (2019) translated BDD-NET 
from Swedish to English and completed the first 
Internet-based, therapist-guided, CBT for BDD with 
global inclusion criteria. Thirty-two patients from nine 
different countries participated in this uncontrolled pilot 
study. BDD symptoms improved significantly over the 
course of the 12-week treatment phase, and therapeutic 
gains were maintained at 3-month follow-up. The study 
showed that ICBT can be safely delivered across interna-
tional borders to patients who otherwise might not have 
access to specialty care.
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Recently, Wilhelm et al. (2020) developed and tested 
the first smartphone CBT app for BDD to examine the 
potential of another low cost, accessible, and standardized 
BDD intervention. The program was developed with 
extensive input from BDD patient consultants as well 
as engineering, design, and clinical psychology experts. 
The app offered CBT skills, and an asynchronous chat 
feature that allowed for brief interactions with a thera-
pist. The 12-week open pilot trial (N = 10) showed that 
smartphone-based CBT for BDD may be feasible, and 
acceptable. In fact, nobody dropped out of the study, and 
treatment satisfaction was high. The study also showed 
improved BDD symptom severity, as well as improved 
BDD-related insight, functional impairment, and quality 
of life. Ninety percent of participants were responders at 
posttreatment and a 3-month follow-up.
These studies are highly encouraging and speak to the 
ability of technology to reach people who either can-
not access face-to-face therapists or who simply prefer 
that mode of delivery. Further studies should compare 
outcomes with face-to-face therapy as well as delineate 
which individuals with BDD are best suited to which 
mode of delivery.
Gaze and eye movements
Distinguishing features of BDD from other OCRDs have 
also been noted regarding gaze and visual perception. 
Reflecting on the tendency of those with BDD to focus 
their attention on specific facial or bodily features that are 
the area of preoccupation, research studies have shown 
an imbalance in the local and global visual processing 
systems within this population (see Beilharz et al., 2017 
for a review). These findings indicate that people with 
BDD display a visual attention bias for specific details 
or features (local), rather than perceiving an image as a 
whole (global), whereas a combination of both strategies 
is effectively used by non-BDD populations (Kimchi, 
1992; Love et al., 1999).
While abnormalities in basic eye movements or sacca-
des have been noted within other psychiatric conditions, 
including OCD, anorexia nervosa, and schizophrenia 
(McDowell et al., 1995; Karoumi et al., 1998; Landgraf et 
al., 2008; Gadel et al., 2012; Phillipou et al., 2014, 2016a), 
there is preliminary evidence that these eye movements 
are generally intact in BDD patients (Beilharz et al., 
2020). It appears likely then, that abnormalities within 
higher-order levels of visual processing, such as patterns 
of scanning complex images, may be responsible for the 
differences in perception apparent among people with 
BDD.
The primary evidence of disrupted higher-order process-
ing in BDD comes from the literature on face processing. 
Individuals with BDD typically have higher error rates 
and slower response times when recognizing the iden-
tity and emotions of face stimuli (Buhlmann et al., 2002, 
2004, 2006, 2011; Feusner et al., 2006, 2010; Jefferies et al., 
2012; Toh et al., 2015; Grace et al.., 2019a). Abnormalities 
in eye movements have also been noted when viewing 
these images, indicating a pattern of ‘hyposcanning’, 
with higher mean saccade amplitude, fewer fixations of 
extended duration and more blinks (Grocholewski et al., 
2012; Greenberg et al., 2014; Toh et al., 2015, 2017a), The 
location of an individual’s gaze can also indicate patterns 
of disrupted perception, as individuals with BDD tend 
to avoid the most salient facial features (eyes, nose, and 
mouth) and instead focus upon or avoid the perceived 
areas of concern. Similar patterns have been noted for 
own and others’ faces among those with BDD, which may 
be analogous to the compulsive behaviours of repeatedly 
checking or avoiding one’s appearance in the mirror or 
comparing it to others.
Given the strong research literature of visual perception 
abnormalities within BDD, specific strategies targeting 
perception are recommended as part of treatment. Within 
CBT, this includes perceptual mirror retraining, where 
individuals are taught to view themselves in a more holis-
tic and non-judgmental manner (Wilhelm et al., 2013, 
2014). Directions for future research also include specific 
visual training programs to support more traditional ther-
apies for BDD, such as cognitive remediation, which has 
effectively been used within other psychiatric disorders 
(Beilharz et al., 2018; Buhlmann et al., 2011). Indeed, as 
with OCD, specific areas of cognitive dysfunction may 
turn out to represent novel treatment targets for peo-
ple with BDD. For example, a small cognitive-affective 
neuroscience study showed that individuals with BDD 
performed poorly on a variety of neurocognitive tests of 
cognitive flexibility, reward and motor impulsivity, and 
affective processing, similar to the areas of cognitive dys-
function seen in OCD. However, these data also hinted 
at additional areas of decision-making abnormality that 
might contribute specifically to the psychopathology of 
BDD (Jefferies et al., 2017).
Oxytocin*
As noted above, one of the most well-replicated empirical 
findings in BDD pertains to poor social cognition, espe-
cially facial affect perception. BDD patients make more 
errors when asked to perceive facial emotions, espe-
cially when viewing neutral and negative expressions. 
Oxytocin* is a neuropeptide that acts as a neurotransmit-
ter and has been documented to be a key modulator of 
complex social behaviours and social cognition through-
out mammalian evolution. It is well-known for its role 
in attachment, social exploration, social recognition, fear 
extinction, and anxiety reduction. Intranasal delivery is 
the most common method of administration, argued to 
provide a direct pathway into the brain. Oxytocin recep-
tors are present in the limbic and reward-related regions 
of the brain, including the amygdala; the amygdala is a 
key region in the ‘social brain’, and these areas are associ-
ated with social cognitive performance.
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Fang et al. (2019) administered intranasal oxytocin (24 
international units) or placebo to 18 BDD patients and 16 
healthy controls, using a within-subject cross-over design. 
They failed to find an effect of oxytocin on emotion rec-
ognition accuracy for either self- or other-referent tasks. 
In the BDD participants, oxytocin actually worsened the 
tendency to internal attributions on other-referent tasks, 
relative to controls. The authors conclude that caution 
needs to be exerted in using oxytocin in BDD.
More recent evidence has established that BDD patients 
exhibit abnormal amygdala-temporal connectivity dur-
ing a resting-state functional magnetic resonance scan, 
and that oxytocin administration (24 international units) 
restored this deficit, increasing connectivity to levels 
equivalent in BDD patients (n = 19) relative to a group 
of healthy controls (n = 17) during their placebo session 
(Grace et al., 2019b). In psychotic disorders, neurobio-
logical change during acute oxytocin trials has shown 
translation into substantial clinical improvements when 
delivered daily (i.e. 6–8 weeks). Thus, the study of 
Grace et al. (2019b) provides promising data and sug-
gests that oxytocin should be further investigated as a 
novel intervention for those with BDD. Such studies 
need to be cognizant; however, of the concerns raised by 
Fang et al. (2019) based on their pilot treatment study 
findings.
Neurostimulation
Although emerging evidence supports the use of neu-
rostimulation paradigms, notably repetitive transcranial 
magnetic stimulation* in OCD, there is substantial var-
iability in the methodology, including anatomical site, 
total number of stimuli per session, duration of trial, fre-
quency, and bilateral vs. unilateral application (Lusicic et 
al., 2018). We are not aware of any published studies spe-
cifically of neurostimulation in BDD, but it would appear 
to be an area worthy of attention. Neuroanatomical tar-
gets and stimulation parameters would not necessarily be 
the same as those used in OCD research; the occipital 
lobe might be a justifiable target, given the prominence 
of visual cortical involvement in neurobiological mod-
els of BDD (see above). To our knowledge, deep brain 
stimulation*, which has been effectively used in cases 
of treatment-refractory OCD, has not been specifically 
studied in BDD and thus its efficacy for this indication 
is unknown.
Electroconvulsive therapy* (ECT) is not usually recom-
mended for BDD; limited case series data suggest that 
it is not typically effective (Phillips, 2017). However, it 
can be considered if there is severe comorbid depres-
sion and high levels of suicidality which would meet 
criteria for ECT in itself, as indicated for patients with 
OCD (American Psychiatric Association, 2007). Mahato 
et al. (2016) reported a case in which both depressive and 
BDD symptoms responded to ECT.
Conclusion
BDD is a common and often severe psychiatric disor-
der. Patients often do not seek help directly from men-
tal health professionals, and sensitive questioning is 
required for case ascertainment. There are established 
screening, diagnostic and outcome measures for BDD. 
The preferences of the patient need to be included in 
treatment planning. The mainstay of pharmacological 
therapy is SRIs*, which often require high doses and 
protracted periods to establish full benefit. SNRIs* may 
be considered as a second-line treatment. Various adjunc-
tive medications can be considered, including atypical 
antipsychotics*, anxiolytics*, and the anticonvulsant 
levetiracetam*; large scale RCTs are; however, lacking. 
BDD is not an approved indication for these medica-
tions because no pharmaceutical company has pursued 
an indication for BDD. The potential role of oxytocin* in 
treating BDD requires further exploration. The first-line 
psychological therapy is CBT that is specifically tailored 
to BDD’s unique clinical features. The nuancing of these 
treatments to address such issues as mirror use, pertur-
bations of gaze, and misinterpretation of the emotions 
of others, is important and may involve specific train-
ing of visual processes. On-line and telephone-assisted 
forms of psychological therapies are emerging and seem 
to be effective and well accepted by patients with BDD, 
although additional studies are needed, including which 
patients with BDD these treatments are best suited for.
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